For verification of this hypothesis, we determined the expression levels of BTLA in CD3+ and CD19+ subpopulations of cells in CLL patients compared to those of healthy controls as well as to the coexpression of another inhibitory molecule CTLA-4 before and after ex vivo stimulation. Here, BTLA is linked to B-cell chronic lymphocytic leukemia.